Useful AMR graphics: Poirel 2017 and Marston 2016

Dear All:

There’s a very comprehensive review of the polymyxins by Poirel, Jayol, and Nordmann just out in Clin Micro Reviews ( If you’re a fan of good quality graphics as way to tell the story of AMR, their Figure 4 is worth capturing! Ditto their Figure 5 of outbreaks of colistin-resistant, carbapenemase-producing K. pneumoniae. Both are shown below.

This paper also reminds me of Marson 2016 (JAMA 316:1193-204, 2016) in which the NIAID team provides two further useful graphics showing how rapidly AMR can develop and spread. Good graphics like these are so very helpful in communication!

Would all of you who are working on new products for Gram-negative rods please get really, really, REALLY busy?

Best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Chief Strategy Officer, CARB-X | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx

Figures 4 and 5 from Poirel L, Jayol A, Nordmann P. Polymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes. Clin Microbiol Rev. 2017;30(2):557-96.



Below left: Time (years) to resistance for new classes. Below right: Recovery of mcr-1-expressing E’bacteriaceae. From Marston HD et al. Antimicrobial Resistance. JAMA. 2016;316(11):1193-204.


Leaky pipe(line)s, Part 2 / CARB-X reboot / WHO 2021 pipeline review

Dear All, We have a 3-part discussion today on the theme of “I want a new drug … so how do I find it?” Off we go! First, the 14 June 2022 newsletter entitled “Leaky Pipe(lines) / When Is A Molecule A Drug” generated further discussions that are worth sharing: It was noted the microdosing

Antibiotic procurement models for LMICs / G7 Leaders call for Pull!

Dear All, Two stops on our tour today: (i) an excellent survey of incentive models and (ii) a final communique from the recent G7 meetings. First up, CGD (Center for Global Development) have released a report (link) entitled “Leveraging Purchasing Systems to Ensure Access, Stewardship, and Innovation: A Landscape Review of Current and Potential Market Structures

Leaky pipe(lines) / When is a molecule a drug? (Part 1 of 2)

Dear All, I was fascinated by this recent paper in AAC: Neha K. Prasad, Ian B. Seiple, Ryan T. Cirz, and Oren S. Rosenberg. Leaks in the Pipeline: a Failure Analysis of Gram-Negative Antibiotic Development from 2010 to 2020. Antimicrob Agents Chemother. 2022 May 17;66(5):e0005422. doi:10.1128/aac.00054-22. (Addendum: This newsletter has a follow-up newsletter.) In brief,

FDA/CVM: Antimicrobial use in companion animals

Dear All, Post-newsletter addendum: I’ve learned that USDA will host a 10 Aug 2022 (virtual, 10a-4.30p ET) workshop on AMR in food agriculture. See the meetings calendar for more details; go here to register. I’ll confess to having missed entirely the request back in February 2022 from FDA’s Center for Veterinary Medicine (CVM) for comments on antimicrobial

Scroll to Top